A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
A phase 1/2 trial of JAB-8263 in non-small-cell lung cancer, small-cell lung cancer and ovarian cancer, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.
Overview
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors is a phase 1/2 interventional study registered as NCT04686682 by Jacobio Pharmaceuticals Co., Ltd., with 152 participants planned, started 2021-05-07 and due to reach its primary completion in 2028-01. Interventions recorded: JAB-8263.
Similar pages
not linked directly; found by shared links- TrialJAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Shares Jacobio Pharmaceuticals, Small-cell lung cancer and the tag pipeline.
- TrialJAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Shares Jacobio Pharmaceuticals and the tag pipeline.
- TrialA Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Shares Jacobio Pharmaceuticals and the tag pipeline.
- TrialJAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Shares Jacobio Pharmaceuticals and the tag pipeline.
- TrialStudy of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
Shares Jacobio Pharmaceuticals and the tag pipeline.
- TrialA Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Shares Ovarian cancer, Small-cell lung cancer and the tag pipeline.
- TrialA Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Shares Ovarian cancer, Small-cell lung cancer and the tag pipeline.
- TrialFiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.